Upgrade to SI Premium - Free Trial

Cogent Biosciences (COGT)

34.76 -0.19 (0.54%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/10/26)

Latest Headlines

Form 144 Cogent Biosciences, Inc. Filed by: Morris Arlene August 27, 2026 4:18 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Cogent (COGT) August 20, 2026 6:53 AM - StreetInsider Cogent (COGT) PT Raised to $55 at Piper Sandler August 17, 2026 7:43 AM - StreetInsider Form SCHEDULE 13G/A Cogent Biosciences, Inc. Filed by: Flynn James E August 13, 2026 4:12 PM - SEC Filing Cogent (COGT) PT Raised to $52 at Guggenheim August 12, 2026 6:53 AM - StreetInsider Form 8-K Cogent Biosciences, Inc. For: Aug 10 August 10, 2026 5:20 PM - SEC Filing Form 424B5 Cogent Biosciences, Inc. August 10, 2026 5:18 PM - SEC Filing Form 10-Q Cogent Biosciences, Inc. For: Jun 30 August 10, 2026 4:12 PM - SEC Filing Form 8-K Cogent Biosciences, Inc. For: Aug 10 August 10, 2026 8:06 AM - SEC Filing Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results August 10, 2026 8:00 AM - Globe NewsWire Cogent Biosciences (COGT) 2K contracts of January 60 calls trade, share price up 10.5% August 4, 2026 1:47 PM - StreetInsider Form SCHEDULE 13G Cogent Biosciences, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC July 31, 2026 9:55 AM - SEC Filing Form SCHEDULE 13G/A Cogent Biosciences, Inc. Filed by: BlackRock, Inc. July 27, 2026 4:27 PM - SEC Filing Form 4 Cogent Biosciences, Inc. For: Jul 01 Filed by: Ferrante Karen Jean July 6, 2026 4:31 PM - SEC Filing Cogent Biosciences files NDA for bezuclastinib in advanced mastocytosis June 30, 2026 8:00 AM - StreetInsider Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) June 30, 2026 8:00 AM - Globe NewsWire H.C. Wainwright Reiterates Buy Rating on Cogent (COGT) June 18, 2026 6:47 AM - StreetInsider Stifel Reiterates Buy Rating on Cogent (COGT) June 15, 2026 9:24 AM - StreetInsider Cogent Biosciences presents preclinical data on JAK2 inhibitor at EHA June 12, 2026 8:01 AM - StreetInsider Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress June 12, 2026 8:01 AM - Globe NewsWire Cogent Biosciences reports 65% response rate in mastocytosis trial June 12, 2026 8:00 AM - StreetInsider Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress June 12, 2026 8:00 AM - Globe NewsWire Form 4 Cogent Biosciences, Inc. For: Jun 09 Filed by: Harwin Peter Evan June 11, 2026 4:31 PM - SEC Filing Form 4 Cogent Biosciences, Inc. For: Jun 09 Filed by: CAIN CHRISTOPHER W. June 11, 2026 4:31 PM - SEC Filing Form 4 Cogent Biosciences, Inc. For: Jun 09 Filed by: Ferrante Karen Jean June 11, 2026 4:31 PM - SEC Filing Form 4 Cogent Biosciences, Inc. For: Jun 09 Filed by: Shegog Todd June 11, 2026 4:30 PM - SEC Filing Form 4 Cogent Biosciences, Inc. For: Jun 09 Filed by: Morris Arlene June 11, 2026 4:30 PM - SEC Filing Form 4 Cogent Biosciences, Inc. For: Jun 09 Filed by: Ros Matthew June 11, 2026 4:30 PM - SEC Filing Form 8-K Cogent Biosciences, Inc. For: Jun 09 June 11, 2026 4:15 PM - SEC Filing Full Article List